Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices
Eurasian Journal of Medical Investigation · 2026 · 37-45
DOI: 10.14744/ejmi.263037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medical Investigation, 2026. Verfasst von Sibel Oyucu Orhan und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Recurrent high-grade gliomas (rHGG) pose a significant challenge with poor prognosis. While bevacizumab plus irinotecan (BEV+IRI) is a frequent salvage regimen, clinical outcomes exhibit substantial inter-patient heterogeneity. Therefore, accessible prognostic biomarkers are needed to identify patients most likely to benefit.
Methods
This retrospective, single-center study enrolled adults with recurrent WHO grade 3–4 gliomas treated with BEV+IRI. Pre-treatment laboratory data were used to calculate Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lym-phocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), Pan-Immune-Inflammation Value (PIV), and hemoglobin, albumin, lymphocyte, platelet (HALP) scores. Optimal cut-offs were determined via receiver operating characteristics (ROC) analysis. Survival was analyzed using Kaplan-Meier and Cox regression models.
Results
In 43 patients, median overall survival (OS) was 9.6 months; median progression free survival (PFS) was 5.8 months. Patients with high pre-treatment NLR (≥6.74) had significantly shorter OS (4.4 vs. 11.4 months; p
Zitieren
APA
Orhan, S. O., Orhan, B., Hasanzade, U., Sali, S., Caner, B., Ocak, B., Şahin, A. B., Deligönül, A., Çubukçu, E., & Evrensel, T. (2026). Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices. Eurasian Journal of Medical Investigation, 37-45. https://doi.org/10.14744/ejmi.263037
Vancouver
Orhan SO, Orhan B, Hasanzade U, Sali S, Caner B, Ocak B, et al. Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices. Eurasian Journal of Medical Investigation. 2026:37-45. doi:10.14744/ejmi.263037
BibTeX
@article{Orhan2026,
author = {Orhan, Sibel Oyucu and Orhan, Bedrettin and Hasanzade, Ulviyya and Sali, Seda and Caner, Burcu and Ocak, Birol and Şahin, Ahmet Bilgehan and Deligönül, Adem and Çubukçu, Erdem and Evrensel, Türkkan},
title = {Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices},
journal = {Eurasian Journal of Medical Investigation},
year = {2026},
pages = {37--45},
doi = {10.14744/ejmi.263037}
}
EUVIMED